Patent · US Active

Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors

US12097203B2 · kind B2 · utility

0Cited by
11References
31Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 4, 2022
Grant dateSep 24, 2024
Priority date—
Expiry dateMay 4, 2042

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/505
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are combinations that include a SHP2 inhibitor and a PD-1 inhibitor and methods of treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.